Dr Horst Lindhofer PhD
Following his PhD thesis at the Ludwig Maximilian's University, Horst Lindhofer moved to the Helmholtz Zentrum München, where he was initially group leader, then head of a clinical cooperation group with Munich's University Hospital. During this time, he laid the foundation for the innovative Triomab® approach and initiated the first clinical studies with trifunctional antibodies. Results were highly encouraging and gave impetus to the foundation of TRION in 1998. Since then, he has developed the company into a successful biopharmaceutical enterprise with state-of-the-art product development capabilities and in-house GMP manufacturing facilities. He has published numerous scientific articles in peer-reviewed journals and won several prestigious awards for his ground-breaking work in the field of cancer immunotherapy.
